InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. (INFU) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for InfuSystem Holdings, Inc. (INFU), covering cash flow, earnings, and balance sheets.
InfuSystem Holdings, Inc. (INFU) Income Statement & Financial Overview
Access detailed annual and quarterly income data for InfuSystem Holdings, Inc. INFU financial performance.
Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
---|---|---|---|---|
Revenue | $36.002M | $34.72M | $33.85M | $35.32M |
Cost of Revenue | $16.13M | $15.55M | $15.63M | $16.27M |
Gross Profit | $19.87M | $19.17M | $18.22M | $19.05M |
Gross Profit Ratio | $0.55 | $0.55 | $0.54 | $0.54 |
R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
SG&A Expenses | $16.34M | $18.55M | $15.35M | $15.53M |
Operating Expenses | $16.34M | $18.55M | $15.60M | $15.78M |
Total Costs & Expenses | $32.47M | $34.10M | $31.23M | $32.05M |
Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
Interest Expense | -$373000.00 | -$336000.00 | $361000.00 | $476000.00 |
Depreciation & Amortization | $0.00 | $3.32M | $3.42M | $3.15M |
EBITDA | $3.78M | $3.91M | $6.05M | $6.41M |
EBITDA Ratio | $0.10 | $0.11 | $0.18 | $0.18 |
Operating Income | $3.78M | $618000.00 | $2.62M | $3.27M |
Operating Income Ratio | $0.10 | $0.02 | $0.08 | $0.09 |
Other Income/Expenses (Net) | -$331000.00 | -$365000.00 | -$352000.00 | -$480000.00 |
Income Before Tax | $3.45M | $253000.00 | $2.26M | $2.79M |
Income Before Tax Ratio | $0.10 | $0.007 | $0.07 | $0.08 |
Income Tax Expense | -$847000.00 | -$520000.00 | $1.33M | -$1.79M |
Net Income | $4.29M | -$267000.00 | $933000.00 | $1.81M |
Net Income Ratio | $0.12 | -$0.008 | $0.03 | $0.05 |
EPS | $0.12 | -$0.01 | $0.04 | $0.08 |
Diluted EPS | $0.12 | -$0.01 | $0.04 | $0.08 |
Weighted Avg Shares Outstanding | $20.97M | $21.13M | $21.27M | $21.29M |
Weighted Avg Shares Outstanding (Diluted) | $21.29M | $21.13M | $21.71M | $21.71M |
Over the past four quarters, InfuSystem Holdings, Inc. demonstrated steady revenue growth, increasing from $35.32M in Q3 2024 to $36.002M in Q2 2025. Operating income reached $3.78M in Q2 2025, maintaining a consistent 10% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $3.78M, reflecting operational efficiency. Net income rose to $4.29M, with EPS at $0.12. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan